• Home
  • Pharmacy Medical Policy Updates

Pharmacy Medical Policy Updates

The following Pharmacy Medical Policy programs have been updated August 1, 2023:

Effective September 1, 2023:

  • Substrate Reduction Therapy
  • Skyclarys
  • Daybue
  • Joenja
  • Biologic Immunomodulators
  • Isturisa
  • Parathyroid Hormone Analog Osteoporosis
  • IL-4 Inhibitor
  • IL-5 Inhibitors
  • Xolair
  • Elagolix/Relugolix
  • Oxybate

Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.

To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization

If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.

Institutional Providers
Professional Providers